Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0EPYFC
ADC Name
SAR-428926
Synonyms
SAR428926; SAR 428926
   Click to Show/Hide
Organization
ImmunoGen, Inc.; Sanofi
Drug Status
Terminated in phase 1
Indication
In total 1 Indication(s)
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Terminated in phase 1
Structure
Antibody Name
Undisclosed
Antigen Name
Lysosome-associated membrane glycoprotein 1 (LAMP1)
  Antigen Info 
Payload Name
Mertansine DM4
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
  Linker Info 
Conjugate Type
Random conjugation through nucleophilic lysines.
Combination Type
Ravtansine
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT02575781
Phase 1
A first-in-human phase 1 dose escalation study of SAR428926 in patients with advanced solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT02575781  Clinical Status Phase 1
Clinical Description A first-in-human phase 1 dose escalation study of SAR428926 in patients with advanced solid tumors.
References
Ref 1 A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.